Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Janssen drug for rare Castleman’s disease

Sylvant approved to treat lymphoma-like condition
FDA headquarters White Oak

The US FDA has approved a new drug to treat a rare cancer-like condition known as multicentric Castleman's disease.

Sylvant (siltuximab), marketed by Johnson & Johnson subsidiary Janssen Biotech, is the first drug backed by the FDA to treat multicentric Castleman's disease, which the agency describes as a rare disorder similar to the blood cancer lymphoma.

Castleman's disease usually occurs in adults with a weakened immune system and is characterised by an abnormal overgrowth of immune cells in lymph nodes and related tissues in the body.

The multicentric form means more than a single group of lymph nodes are affected and patients experience a severely weakened immune system, making it harder to fight infection as well as an increased risk of developing lymphoma.

Due to the severity of the disease and lack of current treatment options Sylvant was assessed by the FDA under its priority review programme. It is also designated an orphan drug due to the rarity of multicentric Castleman's disease

Sylvant's approval does not cover every patient with the disease, however, excluding those who have HIV or human herpes virus 8 (HHV-8), both of which lead to a weakened immune system.

Nevertheless, the approval will be welcomed by Janssen, which demonstrated the safety and effectiveness of Sylvant in its approved indication during a clinical trial of 79 patients who did not have HIV or HHV-8.

The trial showed that 34 per cent of participants treated with Sylvant and best supportive care experienced tumour response, while no participant treated with placebo and best supportive care did.

Sylvant is also under review in the EU where Janssen submitted a drug filing in September last year.

Article by
Thomas Meek

24th April 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....